Halozyme Therapeutics (HALO) Cash from Operations (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Cash from Operations of 180078000.0 for Q1 2026, up 16.77% year-over-year from 154221000.0 in Q1 2025, and down 17.78% quarter-over-quarter from 219029000.0 in Q4 2025.
Halozyme Therapeutics (HALO) Cash from Operations (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Cash from Operations for 17 consecutive years, with 180078000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 16.77% year-over-year to 180078000.0; the TTM figure through Mar 2026 stood at 677415000.0 (up 34.45% YoY), while the FY2025 annual figure was 651558000.0, up 36.01% from the prior year.
- Cash from Operations eased to 180078000.0 in Q1 2026 per HALO's latest filing, from 219029000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 219029000.0 in Q4 2025 and bottomed at 40225000.0 in Q2 2022.
- Historically, Cash from Operations has averaged 114081235.29 across 5 years, with a median of 102354000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 42.8% — and 2023, when it jumped 90.15%.
- Halozyme Therapeutics' Cash from Operations stood at 82453000.0 in 2022, then climbed by 24.14% to 102354000.0 in 2023, then surged by 74.36% to 178467000.0 in 2024, then increased by 22.73% to 219029000.0 in 2025, then retreated by 17.78% to 180078000.0 in 2026.
- Business Quant data shows HALO's Cash from Operations at 180078000.0 in Q1 2026, 219029000.0 in Q4 2025, and 178597000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 240.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 240.89 Mn |
| Jun 30, 2026 | 240.89 Mn |
| Mar 31, 2026 | 180.08 Mn |
| Mar 31, 2026 | 180.08 Mn |
| Dec 31, 2025 | 219.03 Mn |
| Dec 31, 2025 | 219.03 Mn |
| Sep 30, 2025 | 178.60 Mn |
| Sep 30, 2025 | 178.60 Mn |
| Jun 30, 2025 | 99.71 Mn |
| Jun 30, 2025 | 99.71 Mn |
| Mar 31, 2025 | 154.22 Mn |
| Mar 31, 2025 | 154.22 Mn |
| Dec 31, 2024 | 178.47 Mn |
| Dec 31, 2024 | 178.47 Mn |
| Sep 30, 2024 | 115.38 Mn |
| Sep 30, 2024 | 115.38 Mn |
| Jun 30, 2024 | 55.79 Mn |
| Jun 30, 2024 | 55.79 Mn |
| Mar 31, 2024 | 129.43 Mn |
| Mar 31, 2024 | 129.43 Mn |